West Deferred Long Term Liab from 2010 to 2024
| WST Stock | USD 329.57 0.00 0.00% |
Deferred Long Term Liabilities | First Reported 2010-06-30 | Previous Quarter 33.5 M | Current Value 36 M | Quarterly Volatility 9.3 M |
Check West Pharmaceutical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among West Pharmaceutical's main balance sheet or income statement drivers, such as Depreciation And Amortization of 144.2 M, Total Revenue of 3.1 B or Gross Profit of 1.2 B, as well as many indicators such as Price To Sales Ratio of 9.31, Dividend Yield of 0.0021 or PTB Ratio of 9.54. West financial statements analysis is a perfect complement when working with West Pharmaceutical Valuation or Volatility modules.
West | Deferred Long Term Liab |
Latest West Pharmaceutical's Deferred Long Term Liab Growth Pattern
Below is the plot of the Deferred Long Term Liab of West Pharmaceutical Services over the last few years. It is liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue. West Pharmaceutical's Deferred Long Term Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in West Pharmaceutical's overall financial position and show how it may be relating to other accounts over time.
| Deferred Long Term Liab | 10 Years Trend |
|
Deferred Long Term Liab |
| Timeline |
West Deferred Long Term Liab Regression Statistics
| Arithmetic Mean | 20,016,667 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 53.79 | |
| Mean Deviation | 8,084,444 | |
| Median | 20,000,000 | |
| Standard Deviation | 10,766,288 | |
| Sample Variance | 115.9T | |
| Range | 38.4M | |
| R-Value | 0.50 | |
| Mean Square Error | 93.1T | |
| R-Squared | 0.25 | |
| Significance | 0.06 | |
| Slope | 1,214,071 | |
| Total Sum of Squares | 1622.8T |
West Deferred Long Term Liab History
About West Pharmaceutical Financial Statements
West Pharmaceutical shareholders use historical fundamental indicators, such as Deferred Long Term Liab, to determine how well the company is positioned to perform in the future. Although West Pharmaceutical investors may analyze each financial statement separately, they are all interrelated. The changes in West Pharmaceutical's assets and liabilities, for example, are also reflected in the revenues and expenses on on West Pharmaceutical's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Deferred Long Term Liabilities | 38.4 M | 20.2 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for West Stock Analysis
When running West Pharmaceutical's price analysis, check to measure West Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy West Pharmaceutical is operating at the current time. Most of West Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of West Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move West Pharmaceutical's price. Additionally, you may evaluate how the addition of West Pharmaceutical to your portfolios can decrease your overall portfolio volatility.